Thrombo-embolic pulmonary hypertension: which treatment should we choose? /
Hypertension pulmonaire thrombo-embolique: quel traitement choisir ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018
Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far Source: Eur Respir J, 50 (4) 1701725; 10.1183/13993003.01725-2017 Year: 2017
Newly diagnosed patients with chronic thromboembolic pulmonary hypertension and PASP<50 mmHg. Do they need pulmonary endarterectomy? Source: Annual Congress 2005 - News about pulmonary embolism Year: 2005
Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy? Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Diagnosis and treatment of pulmonary hypertension in COPD patients: how far should we go? Source: International Congress 2019 – Lung vessels in COPD: it is time to take them seriously! Year: 2019
The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally! Source: Eur Respir J, 53 (3) 1900038; 10.1183/13993003.00038-2019 Year: 2019
The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Treating pulmonary hypertension in COPD: where do we start? Source: Eur Respir J 2008; 32: 541-542 Year: 2008
Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006
Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease? Source: Eur Respir J, 56 (2) 1902334; 10.1183/13993003.02334-2019 Year: 2020
Pulmonary arterial hypertension: genetics, reversibility testing and follow-up Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=33 Year: 2004
Is there an obesity paradox in pulmonary arterial hypertension? Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017
Pulmonary arterial hypertension or left heart disease with pulmonary hypertension? Toward noninvasive clarity, but time for a new paradigm Source: Eur Respir J 2015; 46: 299-302 Year: 2015
Update on current treatment options of pulmonary hypertension Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005
Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019
Optimising pharmacotherapy in patients with pulmonary arterial hypertension and comorbidities, including lung diseases and heart failure: benefits without harm? Source: International Congress 2018 – Integrated care for patients with pulmonary vascular disease, lung diseases and heart failure Year: 2018
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era}, Source: Eur Respir J 2012; 40: 881-885 Year: 2012
Optimal management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 254-261 Year: 2011
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008